Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNF inhibitor versus intensive combination DMARD therapy in established rheumatoid arthritis
ISRCTN37438295Phase 4Completed
- Sponsor
- King's College London
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of adalimumab, etanercept, infliximab, methotrexate, 5-aminosalicylic acid + sulphasalazine and 5 more in rheumatoid arthritis (RA) (2 arms), sponsored by King's College London. Primary endpoint: Health Assessment Questionnaire at 12 months. Started Apr 2007; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN37438295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN37438295.